GlassScriptPhysician profile
David Allen Brown
NPI 1588655609
$129,492.12
in general payments reported to CMS, 2019-2025
22 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $269 · 2021: $98K · 2022: $2,788 · 2023: $1,142 · 2024: $390 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635 · Travel and Lodging: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,635.48 |
| Travel and Lodging | $109.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $95,000.00 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $20,030.82 | 2019-2021 | |
| Covis Pharma Gmbh | $5,296.11 | 2019 | |
| Optinose US, INC. | $2,500.00 | 2021 | |
| Henry Schein, INC. | $2,500.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $1,671.13 | 2019-2024 | Airsupra, Tezspire |
| Alk-Abello, INC | $616.93 | 2019-2023 | Ragwitek, Odactra, Grastek |
| Genentech USA, INC. | $445.62 | 2019-2024 | Xofluza |
| Blueprint Medicines Corporation | $419.10 | 2023-2025 | Ayvakit |
| Glaxosmithkline, LLC. | $252.67 | 2021-2023 | |
| Siemens Medical Solutions USA, INC. | $143.45 | 2023 | |
| Aquestive Therapeutics, INC. | $119.22 | 2025 | |
| Circassia INC. | $101.29 | 2022 | |
| Grifols USA, LLC | $81.21 | 2021 | |
| Biocryst US Sales Co., LLC | $70.20 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $65.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $50.00 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $38.65 | 2025 | Neffy |
| Greer Laboratories, INC. | $31.13 | 2022 | |
| Jubilant Hollisterstier LLC | $20.71 | 2024 | |
| Aimmune Therapeutics, INC. | $19.71 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.